Follicle-stimulating hormone (FSH) via interaction with G-protein coupled specific receptors plays a central role in the control of gametogenesis in mammals of both sexes. In females, FSH is crucial for follicle growth, follicle maturation and ovulation. FSH receptors, together with luteinizing hormone-chorionic gonadotropin and thyrotropin receptors belong to a subfamily of structurally related receptors within the seven transmembrane receptor family. Among several other regions, the N-terminus of these receptors is believed to be responsible for important specific hormonereceptor contact sites. Recombinant filamentous phages displaying at their surface three overlapping N-terminal decapeptides of the FSH receptor, peptides A18-27, B25-34 and C29-38 were constructed. Ewes and female mice were immunized against the three FSH receptor (FSHR) recombinant phages. Immunoglobulins purified from immunized animals were analyzed for their biochemical properties on a Chinese hamster ovary cell line expressing the porcine FSH receptor. AntiA and antiB immunoglobulins (IgGs) behave as antagonists for 125 I-FSH binding and for FSHdependent cAMP production, while antiC IgGs did not compete for hormone binding. By contrast, antibodies against the C29-38 peptide displayed FSH agonist activity and stimulated the FSH receptor, whereas antiA and antiB IgGs did not. Furthermore, when the FSHR phages were used as peptidic vaccines, they induced a reversible inhibition of ovulation rate in ewes, and impaired fertility in female mice.
INTRODUCTION
Follicle-stimulating hormone (FSH), luteinizing hormone-chorionic gonadotropin (LH-CG) and thyrotropin (TSH) compose the glycoprotein hormone family. Their receptors are structurally and functionally related to the large group of G-protein coupled receptors by their membrane domains, and to the leucine-rich protein family by their large N-terminal extracellular hormone binding domains (Braun et al. 1991 , Kajava et al. 1995 . Due to the large size of both ligands and receptors, the glycoprotein hormones TSH, LH-CG and FSH interact with their receptors through several discontinuous contact sites (Bhowmick et al. 1996 , Remy et al. 1996b , Salesse & Garnier 1996 , some being more involved in positive or negative hormone binding specificity, others in receptor activation and transduction. Although docking models have been elaborated (Lapthorn et al. 1994 , Jiang et al. 1995 , the precise assignment of hormone-receptor contact residues has not been determined yet and will require crystallographic analysis of hormone-receptor complexes. However, the N-terminus cysteine clusters, mostly encoded by the first exon in the receptor genes, has been identified, for the three receptors, as one of the most functionally important sites for ligand binding (Dattatreyamurty & Reichert 1992 , Roche et al. 1992 , Morris et al. 1993 . Although probably conserved in their structure, due to their similarly spaced cysteines, these regions display heterologous primary sequences for the three cognate receptors (TSHR, LH-CGR and FSHR) .
A previous detailed functional study of region 7-40 of the LH-CG receptor, based on the use of synthetic peptides and anti-peptide antibodies, revealed that amino acids 7-24 may be more implicated in ligand recognition while amino acids 25-40 may be more involved in signaling (Couture et al. 1996) . Importantly, a recent study by alanine scanning and cross-linking demonstrated that amino acids 20-38 of the LH-CGR contacts both the and subunits of human CG (hCG) . Thus the important properties of this short receptor-specific sequence renders it a potential target for the design of glycoprotein hormone antagonists or agonists.
Despite the key role of FSH in mammalian reproduction, very limited data on FSH-FSHR interactions are available, when compared with what is known about the LH-CGR and TSHR. This paper aims to demonstrate that, as for the LH and TSH receptors, the N-terminus of the FSH receptor is an essential hormone-receptor contact site, containing binding and signaling specialized areas, and that, by specifically targeting these areas through the immune pathway, FSH-controlled functions can be modulated.
Filamentous phages displaying three different overlapping peptides (A18-27, B25-34 and C29-38 respectively) of the FSH receptor were engineered and used as peptidic vaccines in ewes and mice. Immunoglobulins (IgGs) purified from vaccinated animals were analyzed for their ability to compete with FSH binding and signaling, as well as for their hormone-like activity, using a Chinese hamster ovary (CHO) cell line expressing the FSH receptor. Anti-A18-27 (antiA) and anti-B25-34 (antiB) antibodies were found to be FSH antagonists as they inhibited hormone binding and FSH-induced cAMP production. Anti-C29-38 (antiC) antibodies displayed the opposite properties and behaved as non-competitive FSH agonists able to stimulate the FSH receptor. Moreover, vaccination with phages bearing A18-27 and B25-34 strongly diminished ovulation rates in ewes, whereas all anti-FSHR vaccines affected the fertility of female mice.
MATERIALS AND METHODS

Construction of recombinant phages displaying FSH receptor decapeptides
Hybrid fd-tet phage type 88-4 (a kind gift from Prof. Georges Smith, University of Missouri, Columbia, MO, USA) displays wild-type major coat protein p8 (about 2700 copies per phage) as well as foreign peptide-p8 fusion protein (10-30% of the total p8 protein) interspersed along the phage (Greenwood et al. 1991) . Three pairs of complementary oligonucleotides with compatible PstI and HindIII ends were purchased from GENSET (Paris, France). They encoded three overlapping decapeptides from the human FSHR (A=S18-L27, B=S25-L34, and C=R29-L38) N-terminal region, whose sequences are given in Fig. 1 . Annealed oligonucleotides were ligated to the double-stranded (RF) DNA of PstI-HindIII restricted phage f88-4. Transformation of female electrocompetent MC1061 E. coli yielded tetracycline-resistant colonies. Hybrid p8 protein primary structures were deduced from sequencing the resulting recombinant phages PhA, PhB, and PhC by automated DNA  1. Human FSH receptor (FSHR) overlapping sequences displayed on recombinant phages used as peptidic vaccines. Peptide A18-27 (SKVTEIPSDL), B25-34 (SDLPRNAIEL) and C27-38 (RNAIELRFVL) were fused to the surface coat protein p8 of filamentous phages. Primary sequence alignments of amino acids 11 to 39 of the N-terminus from human, sheep, mouse and pig (interspecies differences are in bold) FSH receptor, as well as for human LH-CG and human TSH receptors are shown.
sequencing (Applied Biosystems, Roissy, France) using a specific p8 primer. Non-recombinant phages particles (f1) expressing the wild-type coat proteins (PhW) were used as control.
Production of phages for immunization
Overnight culture of a single colony of MC1061 E. coli transformed by recombinant or wild-type phage RF-DNA in 1 l NZY medium containing 40 µg/ml tetracycline allowed the recovery of approximately 100 mg polyethylene glycol-precipitated phage particles from supernatants. After solubilization in phosphate saline buffer (PBS, 50 mM pH 7·4 phosphate, 150 mM NaCl) at a concentration of 10 mg/ml and heat sterilization at 70 C for 15 min, phages were kept at 4 C until use.
Estrus synchronization and immunization of ewes
Fourteen cyclic ewes of the Préalpes breed, with a mean ovulation rate of 1·5, between 2 and 5 years old were vaccinated. All animals included in the experiment had previously lambed at least once. One milligram recombinant (or wild-type for control animals) phage antigens was injected subcutaneously without adjuvant for primary or booster immunizations. Ewes were treated with progestagen (intravaginal fluorogestone acetate, 40 mg) for two weeks to synchronize estrus. For the first 'winter' experiment, primary injections were performed three weeks before sponge application, the first booster injection being five days before their withdrawal, and the second between the first (one cycle being 17 days) and the second estrus. Immunoglobulins used for subsequent in vitro analysis were purified from blood taken after the second antigen booster injection. After the winter experiment, animals were allowed to rest without any antigen challenge for a period of seven months. Animals were hormonally resynchronized at the beginning of September for the 'autumn' experiment, and additional antigen injections were performed between the fourth and fifth and between the fifth and sixth estrus.
Immunity
Immune responses were determined at different times in sera from vaccinated ewes, by enzymelinked immunosorbent assay (ELISA) against phages or synthetic peptides representing either FSHR exon 1 or FSHR 15-34 (a kind gift from Dr J M Bidart, IGR, Villejuif, France). Phages or peptides were coated in microtiter wells before applying the different dilutions of antisera in PBS buffer pH 7·4 containing 1% BSA (Sigma, St Quentin Fallavier, France). Incubation times for sera or immunoglobulins purified from sera, as well as for biotinylated rabbit anti-sheep secondary antibodies complexed to steptavidine peroxidase, both used at a dilution of 1/1000 (Amersham, Les Ulis, France) were 1 h at 37 C. The TMB kit (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) was used as peroxidase substrate. Immunoglobulins were affinity purified from antiA, antiB, antiC and antiW sera displaying the highest anti-phage titers, using immobilized Protein A chromatography (Pierce, Rockford, IL, USA). They were then dialyzed against PBS 20 (phosphate 10 mM, NaCl 3·8 mM, KCl 3 mM, CaCl 2 0·9 mM, MgCl 2 0·5 mM, pH 7·4), supplemented with sucrose (230 mM) and BSA (0·5 mg/ml) and redissolved in the same buffer at the indicated concentrations.
Production of a CHO cell line expressing the porcine FSH receptor
The cDNA encoding the porcine FSHR (Remy et al. 1995) was subcloned into the amplifiable glutamine synthetase/CMV vector (Cockett et al. 1990 ). Transfectant clones were selected for resistance to 0·025 mM -methionine sulfoximine (MSX) in glutamine-free GMEM-S medium containing 10% dialyzed calf serum, and for expression of 125 I-FSH specific binding. CHO cells were then plated onto Petri dishes (Falcon, Lincoln Park, NJ, USA) and further selected for resistance to 0·25 mM MSX and maximal expression of functional FSH receptors.
Inhibition binding studies
Purified porcine (p) FSH (a kind gift from Dr Combarnous, Nouzilly, France) was labeled with NaI by the Iodogen method (Pierce) to a specific activity of 40 mCi/mg. For 125 I-FSH binding inhibition studies, cells were plated into 12-well culture dishes. Different concentrations of purified IgG were added (0·25 ml/well), in the presence of a constant amount of 125 I-FSH (200 000 c.p.m./well), for 1 h at 37 C. After removing supernatants, cells were washed with PBS buffer, lyzed with NaOH (1 M), transferred into tubes and counted in a gamma counter (LKB). For each antibody concentration, incubation was also carried out in the presence of an excess of cold hormone (Metrodine, Serono, Boulogne, France), in order to calculate (and substract) non-specific binding for each point. The percentage binding was calculated by dividing sample-specific binding by the maximum specific binding (no IgG added). Assays were performed in triplicate and repeated twice.
Cyclic AMP production
Anti-FSH receptor immunoglobulins were tested for their effects on cAMP production and on FSH-dependent cAMP production by pFSHR-CHO cells. Different concentrations of affinitypurified IgGs from ewe sera were incubated with or without 1 ng/ml FSH (submaximal receptor stimulation) on cell layers in PBS buffer for 1 or 2 h at 37 C. cAMP levels in supernatants were determined using a specific RIA kit (NEN-Dupont de Nemours, Les Ulis, France). All assays were performed in duplicate and repeated twice.
Ovulation rates and progesterone levels in ewes
Evaluation of anti-FSHR vaccination on the ovulation rate of ewes was tested at the end (winter experiment) and beginning (autumn experiment) of the sexual period during three estrous cycles for each experiment. For ovary examinations, ewes were restrained in a cradle; after being locally anesthetized with sylvocaïne at the site of incision, ovaries were observed using a direct vision telescope and an optic fiber light source in conjunction with a cannula with trocar. After removal of telescope and trocar, wounds were dusted with antibiotics and sutured. At each cycle, the number of corpora lutea (CL) were visualized by laparoscopy in both ovaries, one week after the calculated day of ovulation. Blood samples were taken during estrus one and two, and circulating progesterone levels in sera were evaluated by the use of a specific radioimmunoassay.
Female mice vaccinations and fertility
Nine-week-old adult female Balb/c mice (Iffa Credo, l'Arbresle, France) were injected intraperitonaly (i.p.) with 100 µg in 0·1 ml of the respective FSHR phages diluted in sterile PBS without adjuvant. Two booster injections were performed three and four weeks later. Immunized animals were coupled one week after the last antigen challenge with adult untreated partners. The presence of estrus was determined by examination of the vagina. Couples (one per cage) were left together for two weeks; females were then isolated until the progenies from each couple were counted.
Statistical analysis
Analysis of the data was carried out using t-tests and correlation modules of the STATVIEW program on a Macintosh computer.
RESULTS
Immune responses
The time courses of immunoreactivity of mice to recombinant phages have already been analyzed. In a previous study, we have shown that phage particles presenting at their surface around three hundred copies of a receptor peptide were able to induce anti-peptide and anti-receptor immunity. Specificity of the anti-receptor response has also been analyzed in detail: with receptor-specific sequences with no homology (which is the case for sequences encoded by LHR, FSHR or TSHR exon 1, as shown in Fig. 1) , no cross-reactivities between receptors were seen. In contrast, with partly homologous peptides, in vivo and in vitro cross activities have been evidenced (Remy et al. 1996a) .
In order to characterize the vaccine responses in ewes, blood samples from each animal were taken weekly during eight weeks of the first winter experiment and tested individually by ELISA against phages: anti-phage immunity was achieved in ewes using 1 mg antigen injected without adjuvant, although two antigen challenges were necessary to achieve the highest titers. For in vitro experiments, IgGs from the highest immunoresponsive sera, that is a week from the second booster injection, were used. Direct ELISA against FSHR exon 1 (amino acids 1-34 and 15-34) synthetic peptides, as shown in Fig. 2 , indicated FSH receptor anti-peptide immunoreactivity for purified antiA, antiB and antiC IgGs, between 15 and 22% higher than for the antiW IgGs.
Inhibition of 125 I-FSH binding
The pFSHR-CHO cells displayed about 100 000 high affinity FSH receptors per cell (not shown). In order to characterize potential FSH antagonist activities in the anti-phage IgG fractions, 200 000 c.p.m.
125 I-FSH and increasing concentrations of affinity-purified IgGs from antiA, antiB, antiC and antiW antisera, with or without an excess of cold hormone, were coincubated on plated pFSHR-CHO cells. At the concentrations tested (from 2 µg/ml to 2 mg/ml), antiA and antiB IgGs were able to compete with the binding of 125 I-FSH to its receptor (Fig. 3) , up to 40% of the FSH specific binding measured in the absence of IgGs.
In contrast, no or little inhibition (7% at 2 mg/ml) was observed with the antiC IgGs whatever the concentration used, while IgGs from wild-type phage-immunized sera inhibited 15% of the specific FSH binding at the highest concentration.
Inhibition of FSH-induced cAMP
The effects of anti-phages IgGs on hormonestimulated cAMP production were investigated. pFSHR cells were coincubated for 1 h at 37 C with an amount of purified pFSH able to induce a submaximal cAMP production (1 ng/ml made the cells produce 50 pmoles cAMP/ml), together with increasing concentrations of anti-phage immunoglobulins, up to 1·2 mg/ml. As shown in Fig. 4 , IgGs from antiA-and antiB-vaccinated animals almost totally inhibited in a dose-dependent manner the FSH-induced production of second messenger by pFSHR-CHO cells from 50 to 2·5 pmoles/ml (95% inhibition). AntiC IgGs, at the same concentrations, had no influence on FSH-induced cAMP production whereas control IgGs induced nonspecific inhibition of the FSH signal, up to 40% at the highest concentrations of IgGs.
Induction of cAMP by antiC immunoglobulins
In order to observe direct effects of the antireceptor antibodies on the FSH receptor, increasing concentrations of immunoglobulins were incubated with pFSHR-CHO cells for different time periods at 37 C. As shown in Fig. 5 , up to a concentration of 4 mg/ml, none of the antiA, antiB or antiW IgGs were able to modify the basal level of cAMP production induced by cell medium. In contrast, antiC IgGs stimulated the FSH receptor in a dose-(from 2 mg/ml to 4 mg/ml) and time-(1-or 2-h incubations at 37 C, for C 1 h and C 2 h  2. Anti-FSH receptor N-terminus immunoreactivity in sera of ewes. Immunoglobulins were affinity purified from ewes immunized with vaccines A, B, C and W, and applied to synthetic peptides-coated wells at a concentration of 0·1 mg/ml. Two different peptides representing FSHR 1-34 or FSHR 16-34 were tested in duplicate. 
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Effect of anti-FSH receptor vaccinations on ovulation rate in ewes
Ovaries of ewes vaccinated with vaccines A, B, C, ABC (a mixture of the three A, B and C phages), or W (wild-type phage) were examined by laparoscopy for three estrus periods during winter (1, 2 and 3) and three estrus periods (4, 5 and 6) during autumn. The numbers of CL were counted. The evolution of ovulation rates for animals under the antagonist vaccines A, B or ABC was identical, thus data were pooled and shown in Fig. 6A . The ovulation rates of animals treated with vaccines C or W were different and shown in Fig. 6B . Due to the vaccination protocol, estrus 1 already occurred under immunization. Antagonist vaccines inhibited ovulation as soon as estrus 2 (mean of 1·1 0·2, P<0·05 when compared with controls W) while at estrus 3, the ovulation rate was strongly diminished (mean of 0·6 0·23, P<0·01 when compared with estrus 1).
Possibly due to the early seasonal influence on estrus, wild-type W phage-vaccinated ewes did not ovulate at estrus 3. AntiC-vaccinated ewes were also inhibited at estrus 2 and 3. In order to delineate the relative influence of the treatment vs season on ewe anovulation, as well as the reversibility of the anti-ovulatory effects of the vaccines, ewes were left for seven months without antigen challenge and synchronized by steroids one month after the beginning of the next sexual season. As shown in Fig. 6 , at the first autumn estrus (estrus 4) ovulation rates were fully restored in all animals and were even higher than the average for this breed. Antigen challenges were then performed again, and the effects of these booster injections on ovulation rates were observed at estrus 5 and 6. For the antagonists vaccine groups (Fig. 6A) , a clear decrease in ovulation rates was observed between estrus 4 and 5 (from 1·88 0·2 to 1·1 0·2, P<0·01), and between  4. Effect of anti-FSHR phages immunoglobulin purified from vaccinated ewes on FSH-dependant cAMP production in pFSHR-CHO cells. Cells were incubated for 1 h at 37 C with 1 ng/ml purified porcine FSH per well with the indicated concentrations of antiA (), antiB (), antiC (), or antiW () ewes' purified IgGs. Production of cAMP under stimulation of FSH and anti-FSH receptor IgGs was evaluated twice in duplicate in cell supernatants.
 5. Agonist effect of anti-peptide C27-38 antibodies. Effect of anti-FSH receptor (A, B and C) or anti-wild-type phage (W) immunoglobulins on cAMP production by pFSHR-CHO cells. IgGs from ewes' antisera were purified and added to cell culture wells at the indicated concentrations in PBS buffer for 1 h for C 1 h or 2 h for C 2 h at 37 C. Accumulations of cAMP (pmoles/ml) in supernatants were determined twice by RIA in duplicate. Means .. are given for 3 and 4 mg/ml IgGs. estrus 5 and 6 (from 1·1 0·2 to 0·2 0·2, P<0·01). Meanwhile, there was no change in ovulation rates at estrus 4, 5 and 6 for antiC-and antiW-vaccinated animals, as shown in Fig. 6B .
Progesterone concentrations in individual sera from vaccinated ewes were measured at estrus 2 in order to correlate hormone levels with laparoscopy observations. Circulating progesterone is mainly produced by ovulated CL which maintain a plateau level of 2-3 ng/ml from around day 8 to day 15 after ovulation. On day 7 after estrus 2, we measured a mean of 0·36 0·2 ng/ml in animals found anovulatory by laparoscopy, 1·7 0·2 ng/ml when only one CL was present, and 2·42 0·7 ng/ml when two or three CL were present.
Female mice fertility
Adult female Balb/c mice proven to be fertile were vaccinated with the different anti-FSH receptor phages and wild-type phage as control. All females were examined daily and showed external signs of estrus (swelling) before coupling. Matings with untreated males lasted one week. Females were then isolated and the number of pups counted. As shown in Fig. 7 , all three anti-FSH receptor vaccines provoked inhibition of female prolificacy, while anti-wild phage-vaccinated controls remained unaffected. Using vaccines A and C, more than 80% of the females did not give birth (P<0·01 when compared with W-vaccinated groups), while the B vaccine sterilized half of the treated females. 
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DISCUSSION
In agreement with the view of the N-terminal cysteine cluster as a critical hormone binding region, antibodies against sequences A18-27 and B25-34 of the FSH receptor antagonized FSH binding and, as a consequence, FSH-dependent signaling. These results indicate that the areas defined by these peptides should be surfaceoriented and accessible to antibodies in the membrane-inserted FSH receptors. Due to their heterologous amino acid sequences, the glycoprotein hormone receptors N-terminus might not interact with conserved sequences in hormones: they could either participate positively to hormone discrimination by binding a hormone specific idiotope part of the -subunit determinants, or contribute to hormone segregation by preventing binding of any cognate glycoprotein hormone of the family. Whatever the concentrations used, antiA or antiB antibodies never showed any stimulatory activity of the receptor by themselves.
Antibodies against the more distal sequence C29-38 of the FSHR N-terminus failed to impair in vitro hormone binding or hormone-dependent cAMP production at the concentrations used. This could have resulted from an absence of anti-receptor immunoglobulins in the sera, or from epitope inaccessibility. Nevertheless, at higher doses, these antibodies did show dose-and time-dependent ability to stimulate the FSH receptor. Synthetic peptides 21-36 and 25-40 from the N-terminus of the LH receptor have been shown to display opposite properties: 21-36 behaved as an efficient competitor of LH binding while 25-40 inhibited LH-induced cAMP production (Couture et al. 1996) , suggesting a very close functional topology for the LH and FSH receptors in this region. Despite the inability of antiC IgG to antagonize FSH binding (at the concentrations used in our in vitro assay), the C29-38 area may also represent a hormone-receptor contact site . In this case, due to its diversity between receptors, sequence 29-38 would also interact with part of the hormone-specific -subunit.
Thus, interacting via pharmacological means or via the immune system with the glycoprotein hormone receptors through the area defined by peptides A18-27 and B25-34 may represent a way to generate hormone-specific antagonists, while the area close to peptide C29-38 may represent a way to generate hormone-specific agonists.
A very limited number of physiopathological situations associated with a lack of FSH secretion (Mathews et al. 1993) or with FSHR genetic defects (Aittomaki et al. 1995 , Taipanainen et al. 1997 have been reported in man. The recent report of FSH subunit as well as FSH receptor gene inactivation by homologous recombination in mice can be considered as a phenocopy of a receptor inactivating mutation (Kumar et al. 1997 , Sairam et al. 1998 . It seems clear from these reports that FSH loss of function in females, due either to the absence of circulating hormone or to receptor inactivation, results in infertility due to ovarian dysgenesis by impairment of follicular growth and maturation. However, fertility through completion of follicular maturation can be fully restored by FSH as long as the receptor is still functional, suggesting that no irreversible ovarian damage resulted from the absence of FSH or from FSH receptor inactivation.
All this strongly supports the idea that new fertility control strategies in the female could possibly be based on a reversible inhibition of follicular growth by antagonizing FSH activity.
We found that peptidic vaccines A18-27 and B25-34, while impairing FSH binding to its receptor in vitro were able to provoke an inhibition of ovulation in ewes; anovulation in ewes was found to be reversible with time since the mean number of CL was fully restored with time. Anti-FSH receptor vaccines were also efficient inhibitors of female mice fertility.
It may be rather expected that no significant differences would be observed between the in vivo effects of the three vaccines: one has to consider the antiC IgGs as hormone-like, and long-term stimulation of receptors by their ligands or by stimulating antibodies is known to induce desensitization. Having demonstrated the agonistic effects of antiC antibodies in vitro indicates that this sequence could be targetted for a specific acute stimulation of the receptor.
However, more work is needed in different species, including primates to know to what extent anti-FSHR vaccination in females can reproduce the phenotype of primary amenorrhea of genetic origin (Aittomaki et al. 1996) , as well as for the development of future contraceptive methods based on reversible FSH antagonism in women.
